These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32610561)

  • 1. Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus.
    Utrilla-Trigo S; Jiménez-Cabello L; Alonso-Ravelo R; Calvo-Pinilla E; Marín-López A; Moreno S; Lorenzo G; Benavides J; Gilbert S; Nogales A; Ortego J
    Vaccines (Basel); 2020 Jun; 8(3):. PubMed ID: 32610561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A protective bivalent vaccine against Rift Valley fever and bluetongue.
    Calvo-Pinilla E; Marín-López A; Moreno S; Lorenzo G; Utrilla-Trigo S; Jiménez-Cabello L; Benavides J; Nogales A; Blasco R; Brun A; Ortego J
    NPJ Vaccines; 2020; 5(1):70. PubMed ID: 32793399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Brun A; Anguita J; Ortego J
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.
    Calvo-Pinilla E; Navasa N; Anguita J; Ortego J
    PLoS One; 2012; 7(4):e34735. PubMed ID: 22514660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E; Rodríguez-Calvo T; Sevilla N; Ortego J
    Vaccine; 2009 Dec; 28(2):437-45. PubMed ID: 19857449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
    Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
    Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.
    Martín V; Pascual E; Avia M; Peña L; Valcárcel F; Sevilla N
    PLoS One; 2015; 10(11):e0143273. PubMed ID: 26619062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-/-) mice.
    de la Poza F; Marín-López A; Castillo-Olivares J; Calvo-Pinilla E; Ortego J
    Virus Res; 2015 Dec; 210():149-53. PubMed ID: 26272673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.
    Moreno S; Calvo-Pinilla E; Devignot S; Weber F; Ortego J; Brun A
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008942. PubMed ID: 33275608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination With Recombinant Adenoviruses Expressing the Bluetongue Virus Subunits VP7 and VP2 Provides Protection Against Heterologous Virus Challenge.
    Rojas JM; Barba-Moreno D; Avia M; Sevilla N; Martín V
    Front Vet Sci; 2021; 8():645561. PubMed ID: 33778041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Modified Vaccinia Virus Ankara Development to Express VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Utrilla-Trigo S; Jiménez-Cabello L; Ortego J
    Methods Mol Biol; 2022; 2465():177-193. PubMed ID: 35118622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus.
    Andrew M; Whiteley P; Janardhana V; Lobato Z; Gould A; Coupar B
    Vet Immunol Immunopathol; 1995 Aug; 47(3-4):311-22. PubMed ID: 8571549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Ortego J
    Methods Mol Biol; 2016; 1349():137-50. PubMed ID: 26458834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of a conserved region of bluetongue virus protein VP2 in cross-neutralisation of bluetongue virus serotypes.
    Jyothi SJ; Patil SR; Reddy NY; Panduranga RP; Madala U; Prakash GM; Putty K
    Onderstepoort J Vet Res; 2020 Oct; 87(1):e1-e6. PubMed ID: 33054261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.